PhUSE 2014

PHASTAR are attending the PhUSE Conference.

PHASTAR will be exhibiting at the 2014 PhUSE Annual Conference in London at stand number 15. You can discuss any statistical consulting or clinical trial reporting projects you may be looking to outsource. Alternatively, if you are considering the next step in your career, we'd be delighted to tell you the details of our current campaign, where you can get a sign-on bonus of up to £2000 if you join PHASTAR (more details here).

Land 2 grand

Looking to Lead? Land 2 Grand.

As strong demand for PHASTAR's services continues, we are looking to expand our team, specifically with senior statisticians and programmers. PHASTAR are offering a one-time sign-on bonus of up to £2000* to senior statisticians and programmers signing up to join PHASTAR before October 31st 2014, payable to the individual joining the company.

We will be at the PhUSE 2014 conference on stand 15. Please come and speak to one of the team for more information, or to apply.

Continue Reading

PHASTAR DONATES COMPUTER PROGRAMS TO FDA/PhUSE REPOSITORY

PHASTAR donates SAS programs to FDA/PhUSE Open Source Repository

PHASTAR has today released two SAS useful macros to be available free of charge in the newly launched open source FDA/PhUSE repository.  Both macros can create a large number of tables within a clinical trial report.  One creates tables of summary statistics for continuous and/or categorical data (for example, tables of demographics).  The other creates tables of event counts, such as adverse events, or the number of patients taking specific medications, in a clinical trial.

We believe that pharmaceutical companies should focus their efforts in developing innovative new medicines, and that software development should be either done collaboratively, or left to software development experts.  We hope that our donation - one of the first in the FDA/PhUSE repository - will encourage others to donate useful SAS, R, STATA, S+ or other scripts and tools to the statistical and programming community, and we wish the FDA/PhUSE team success in their new venture.